Search Results - "WOLFF, Debra A"

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy by Lyman, Gary H., Kuderer, Nicole M., Crawford, Jeffrey, Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Dale, David C.

“…BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving…”
Get full text

Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review by LYMAN, Gary H, DALE, David C, WOLFF, Debra A, CULAKOVA, Eva, PONIEWIERSKI, Marek S, KUDERER, Nicole M, CRAWFORD, Jeffrey

“…To evaluate the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and overall mortality in patients receiving chemotherapy with or without…”
Get full text

Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens by GRIGGS, Jennifer J, CULAKOVA, Eva, SORBERO, Melony E. S, PONIEWIERSKI, Marek S, WOLFF, Debra A, CRAWFORD, Jeffrey, DALE, David C, LYMAN, Gary H

“…Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social…”
Get full text

Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy by GRIGGS, Jennifer J, CULAKOVA, Eva, SORBERO, Melony E. S, VAN RYN, Michelle, PONIEWIERSKI, Marek S, WOLFF, Debra A, CRAWFORD, Jeffrey, DALE, David C, LYMAN, Gary H

“…The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in…”
Get full text

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study by Culakova, Eva, Poniewierski, Marek S, Wolff, Debra A, Dale, David C, Crawford, Jeffrey, Lyman, Gary H

“…Background Febrile neutropenia (FN) is a major dose-limiting toxicity of cancer chemotherapy resulting in considerable morbidity, mortality, and cost. This…”
Get full text

Variation in the cost of medications for the treatment of colorectal cancer by Ferro, Salvatore A, Myer, Brian S, Wolff, Debra A, Poniewierski, Marek S, Culakova, Eva, Cosler, Leon E, Scarpace, Sarah L, Khorana, Alok A, Lyman, Gary H

“…To evaluate the economic burden of colorectal cancer (CRC) treatment on the healthcare system as treatment costs have risen 340-fold during the past 5 years…”
Get full text

Impact of a Rural Domestic Violence Prevention Campaign by Gadomski, Anne M., Tripp, Maria, Wolff, Debra A., Lewis, Carol, Jenkins, Paul

“…Domestic violence is a prevalent health problem that in rural areas is further complicated by limited services, social isolation and the lack of privacy…”
Get full text

Registered Nurses Return to College: Lessons Learned from Hindsight by Wolff, Debra A

“…The recent impetus to increase the number of baccalaureate-prepared nurses comes from within and outside the profession, prompting increased numbers of…”
Get full text

A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients by Lyman, Gary H., Crawford, Jeffrey, Kuderer, Nicole M., Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Dale, David C.

“…Anemia represents the most common hematological toxicity in cancer patients receiving systemic chemotherapy and is associated with considerable morbidity and…”
Get full text

Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy by Lyman, Gary H., Dale, David C., Kuderer, Nicole M., Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Crawford, Jeffrey

“…Anemia represents the most common hematological toxicity in cancer patients receiving chemotherapy and is associated with considerable morbidity and cost…”
Get full text

Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study by Dale, David C., Crawford, Jeffrey, Wolff, Debra A., Poniewierski, Marek S., Culakova, Eva, Lyman, Gary H.

“…Background: Chemotherapy-induced neutropenia is frequently associated with neutropenic complications resulting in reduced relative dose intensity (RDI)…”
Get full text

First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study by Crawford, Jeffrey, Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Selby, Caleb, Dale, David C., Lyman, Gary H.

“…Introduction: Myelosuppression represents the major dose-limiting toxicity of cancer chemotherapy. This prospective, nationwide study was undertaken to better…”
Get full text

Assessment of Hematologic and Non-Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Registry by Tahir, Naeem, Goldschmidt, Jerome H., Culakova, Eva, Poniewierski, Marek S., Wolff, Debra A., Dale, David C., Crawford, Jeffrey, Lyman, Gary H.

“…Introduction: Although 60% of all malignancies occur in patients ≥65, this population is poorly represented in cancer clinical trials. While fit elderly…”
Get full text

P-688 Patterns of care and risk of chemotherapy-induced neutropenia and anemia in patients with lung cancer: Preliminary results from a prospective registry for risk model development by Crawford, Jeffrey, Dale, David, Wolff, Debra A., Agboola, Olayemi, Lyman, Gary H.

Get full text